Nature Search

Functional and structural basis of human parainfluenza virus type 3 neutralization with human monoclonal antibodies

Monoclonal antibodies from people after natural human parainfluenza virus type 3 infection can protect from infection in vitro and in vivo by targeting both pre-fusion F and haemagglutinin-neuraminidase HN proteins of the virus.

Naveenchandra Suryadevara
Ana Rita Otrelo-Cardoso
James E. Crowe Jr.
Research10 Jun 2024
Nature Microbiology

Volume: 9, P: 2128-2143
Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

B cell receptor sequencing with ligand blocking speeds up neutralizing antibody discovery.

Andrea R. Shiakolas
Kevin J. Kramer
Ivelin S. Georgiev
Research03 Mar 2022
Nature Biotechnology

Volume: 40, P: 1270-1275
Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Sanz and colleagues examine B cell subsets in a cohort of patients with COVID-19. Severely ill patients have higher frequencies of activated extrafollicular T-bet⁺ B cells that form antibody-secreting cells, the majority of which express germline sequences and are reminiscent of antibody responses observed in patients with systemic lupus erythematosus during flares.

Matthew C. Woodruff
Richard P. Ramonell
Ignacio Sanz
Research07 Oct 2020
Nature Immunology

Volume: 21, P: 1506-1516
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

A comprehensive analysis of antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants shows markedly diminished neutralizing activity against the variant B.1.351, first identified in South Africa.

Rita E. Chen
Xianwen Zhang
Michael S. Diamond
Research04 Mar 2021
Nature Medicine

Volume: 27, P: 717-726
Potently neutralizing and protective human antibodies against SARS-CoV-2

An analysis identifies human monoclonal antibodies that potently neutralize wild-type SARS-CoV-2 and protect animals from disease, including two that synergize in a cocktail, suggesting that these could be candidates for use as therapeutic agents for the treatment of COVID-19 in humans.

Seth J. Zost
Pavlo Gilchuk
James E. Crowe Jr
Research15 Jul 2020
Nature

Volume: 584, P: 443-449
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine

Vaccination against COVID-19 has shown activation of different immune cell types. Here the authors characterise the immune response to the SARS-CoV-2 mRNA vaccine using longitudinal CyTOF single cell approaches to characterise antigen specific B and T-cell responses promoted by this vaccine.

Kevin J. Kramer
Erin M. Wilfong
Jonathan M. Irish
ResearchOpen Access16 Jun 2022
Nature Communications

Volume: 13, P: 1-20
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

A platform for rapid antibody discovery enabled the isolation of hundreds of human monoclonal antibodies against SARS-CoV-2 and the prioritization of potent antibody candidates for clinical trials in patients with COVID-19.

Seth J. Zost
Pavlo Gilchuk
James E. Crowe Jr.
Research10 Jul 2020
Nature Medicine

Volume: 26, P: 1422-1427
A molecular signature of lung-resident CD8⁺ T cells elicited by subunit vaccination

Naveenchandra Suryadevara
Amrendra Kumar
Sebastian Joyce
ResearchOpen Access09 Nov 2022
Scientific Reports

Volume: 12, P: 1-17

Search

Filter By:

Search

Quick links